Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1985 Nov;86(3):737–741. doi: 10.1111/j.1476-5381.1985.tb08953.x

The effect of chronic haloperidol treatment on some cardiovascular parameters in cats.

G A Bentley, I W Copeland
PMCID: PMC1916745  PMID: 4063587

Abstract

Blood pressure, heart rate and evoked cardiovascular reflexes were examined in cats following chronic treatment with haloperidol, at a dose of 1 mg kg-1 per day, orally for 23 days. Five days after the final dose the animals were anaesthetized and tested for their reaction to various cardiovascular stimuli and to a number of agonist and antagonist drugs, given both intravenously and into the vertebral artery. It was found that treatment with haloperidol caused hypertension in the cats, as well as a potentiation of the pressor response to bilateral carotid occlusion. The response to 30 degrees head-up tilting was also altered so that in treated cats, the blood pressure returned to normal more rapidly during the tilt. There was no difference in the heart rate of the two groups of cats, nor in the pressor response to intravenous noradrenaline or angiotensin II or to afferent brachial nerve stimulation, nor was the depressor action of bradykinin altered. Hexamethonium reduced the blood pressure in both control and treated cats to approximately the same level. Blood O2, CO2, pH and bicarbonate levels were also unaltered by the treatment, as was plasma renin activity. Of the drugs given into the vertebral artery, only noradrenaline, prazosin, ketanserin and haloperidol caused a significantly greater fall in blood pressure in treated than in control cats, while clonidine and St91 were equally effective in both groups. These results suggest that haloperidol treatment has caused a greater modulation of central alpha 1- than of alpha 2-adrenoceptors.

Full text

PDF
737

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andén N. E., Butcher S. G., Corrodi H., Fuxe K., Ungerstedt U. Receptor activity and turnover of dopamine and noradrenaline after neuroleptics. Eur J Pharmacol. 1970;11(3):303–314. doi: 10.1016/0014-2999(70)90006-3. [DOI] [PubMed] [Google Scholar]
  2. Andén N. E., Gomes C., Persson B., Trolin G. R 28935 and prazosin: effects on central and peripheral alpha-adrenoreceptor activity and on blood pressure. Naunyn Schmiedebergs Arch Pharmacol. 1978 May;302(3):299–306. doi: 10.1007/BF00508299. [DOI] [PubMed] [Google Scholar]
  3. Bannon M. J., Bunney E. B., Zigun J. R., Skirboll L. R., Roth R. H. Presynaptic dopamine receptors: insensitivity to kainic acid and the development of supersensitivity following chronic haloperidol. Naunyn Schmiedebergs Arch Pharmacol. 1980 Jun;312(2):161–165. doi: 10.1007/BF00569725. [DOI] [PubMed] [Google Scholar]
  4. Dunstan R., Jackson D. M. Further evidence for a change in central alpha-adrenergic receptor sensitivity after withdrawal from long-term haloperidol treatment. Naunyn Schmiedebergs Arch Pharmacol. 1978 Jun;303(2):153–156. doi: 10.1007/BF00508061. [DOI] [PubMed] [Google Scholar]
  5. Dunstan R., Jackson D. M. Long-term haloperidol-treatment of mice: a change in beta-adrenergic receptor responsiveness. J Neural Transm. 1979;44(3):187–195. doi: 10.1007/BF01253062. [DOI] [PubMed] [Google Scholar]
  6. Dunstan R., Jackson D. M. The demonstration of a change in adrenergic receptor sensitivity in the central nervous system of mice after withdrawal from long-term treatment with haloperidol. Psychopharmacology (Berl) 1976 Jul 9;48(1):105–114. doi: 10.1007/BF00423315. [DOI] [PubMed] [Google Scholar]
  7. Dunstan R., Jackson D. M. The effect of apomorphine and clonidine on locomotor activity in mice after long term treatment with haloperidol. Clin Exp Pharmacol Physiol. 1977 Mar-Apr;4(2):131–141. doi: 10.1111/j.1440-1681.1977.tb02613.x. [DOI] [PubMed] [Google Scholar]
  8. Head M., Lal H., Puri S., Mantione C., Valentino D. Enhancement of morphine analgesia after acute and chronic haloperidol. Life Sci. 1979 May 28;24(22):2037–2043. doi: 10.1016/0024-3205(79)90076-6. [DOI] [PubMed] [Google Scholar]
  9. Janssen P. A., Niemegeers C. J., Schellekens K. H., Dresse A., Lenaerts F. M., Pinchard A., Schaper W. K., van Nueten J. M., Verbruggen F. J. Pimozide, a chemically novel, highly potent and orally long-acting neuroleptic drug. I. The comparative pharmacology of pimozide, haloperidol, and chlorpromazine. Arzneimittelforschung. 1968 Mar;18(3):261–279. [PubMed] [Google Scholar]
  10. Kamer R. S., Turi A. R., Solomon P. R., Kaplan L. J. Increased mesolimbic dopamine binding following chronic haloperidol treatment. Psychopharmacology (Berl) 1981;72(3):261–263. doi: 10.1007/BF00431827. [DOI] [PubMed] [Google Scholar]
  11. Lang W. J., Brown M. L., Gershon S., Sletten I., Korol B. Effects of chronic chlorpromazine administration upon the blood pressure responses to autonomic drugs in conscious dogs. Arch Int Pharmacodyn Ther. 1966 Aug;162(2):330–344. [PubMed] [Google Scholar]
  12. Muller P., Seeman P. Brain neurotransmitter receptors after long-term haloperidol: dopamine, acetylcholine, serotonin, alpha-noradrenergic and naloxone receptors. Life Sci. 1977 Dec 15;21(12):1751–1758. doi: 10.1016/0024-3205(77)90155-2. [DOI] [PubMed] [Google Scholar]
  13. Nielsen I. M., Christensen A. V., Hyttel J. Adaptational phenomena in neuroleptic treatment. Adv Biochem Psychopharmacol. 1978;19:267–274. [PubMed] [Google Scholar]
  14. Philippu A., Przuntek H., Heyd G., Burger A. Central effects of sympathomimetic amines on the blood pressure. Eur J Pharmacol. 1971 Jul;15(2):200–208. doi: 10.1016/0014-2999(71)90174-9. [DOI] [PubMed] [Google Scholar]
  15. Philippu A., Stroehl U. beta-Adrenoreceptors of the posterior hypothalamus. Clin Exp Hypertens. 1978;1(1):25–38. doi: 10.3109/10641967809068593. [DOI] [PubMed] [Google Scholar]
  16. Starke K. Alpha-adrenoceptor subclassification. Rev Physiol Biochem Pharmacol. 1981;88:199–236. [PubMed] [Google Scholar]
  17. Van Nueten J. M., Janssen P. A., Van Beek J., Xhonneux R., Verbeuren T. J., Vanhoutte P. M. Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors. J Pharmacol Exp Ther. 1981 Jul;218(1):217–230. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES